First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...

Luke Coutinho mentions Vitamin D3 is a hormone that activates killer immune cells (NK, T-cells), calms dangerous inflammation ...

Your immune system is your body’s built-in defense network, working nonstop to protect you from bacteria, viruses, and other harmful invaders. Your immune ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Using single-cell epigenomic profiling of immune cells from 110 individuals, researchers show that genetic variation and ...

CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.

Adoptive cell therapies (ACT) have become a transformative force in cancer immunology, offering powerful platforms for targeting both hematological and ...

The COVID-19 pandemic gave us tremendous perspective on how wildly symptoms and outcomes can vary between patients ...

GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of immune ...